

Our Commitment

- ❖ We are committed to helping improving access for patients in areas where our therapy is not approved.
- ❖ We evaluate requests to determine that the provision of drug will in no way intervene with ongoing clinical trials, regulatory approval or future patient access.
- ❖ We support patients who have a serious or life-threatening disease where no treatment options are available.
- ❖ We ensure that the provision of drug in no ways compromises the supply to patients currently on therapy.
- ❖ We abide by all local, regional, national and global regulations and laws when permitting access for individual patients.
- ❖ We never implement access to unapproved medicines in any country in a way that could be construed as marketing or promotion of a product prior to regulatory approval.

Who We Are

About Us

We are dedicated to bringing innovative medicines to patients with debilitating rare diseases.

Contact Us

To learn more about the program please contact your lomitapide medical representative or visit the Expanded Access Program section of our website, www.novelion.com.



**LOMITAPIDE
EXPANDED
ACCESS
PROGRAM**

Aegerion
Pharmaceuticals
A NOVELION THERAPEUTICS COMPANY

**LOMITAPIDE EXPANDED
ACCESS PROGRAM**
One Main Street
Cambridge, MA 02142



We have established an Expanded Access Program for lomitapide.

The program has certain clinical eligibility criteria.

Pediatric patients with homozygous familial hypercholesterolemia (HoFH) may be eligible for access to lomitapide if they meet the following criteria:

Pediatric HoFH (<18 years):

- Established diagnosis of HoFH,
- Clinically evident cardiac disease (e.g. CAD, valvular stenosis, MI, interventions),
 - Patients less than 5 years of age without evidence of cardiac disease will be considered
- LDL-C \geq 300 mg/dL (\geq 7.7 mmol/L),
- No known contraindications to the use of lomitapide

“Our aim is to be a catalyst of change, easing the burden on these individuals by educating the community, developing transformative therapies and offering comprehensive support for patients living with certain rare diseases.”

*~Pamela Foulds, MD
Chief Medical Officer, Aegerion*

Are you offering the Lomitapide Expanded Access Program in my country?

In order to determine if we are able to provide lomitapide to your patient in your country, please contact your lomitapide medical representative, or email us at aegerionEAP@aegerion.com.



How do I apply for the Lomitapide Expanded Access Program?

If you are interested in enrolling in the Lomitapide Expanded Access Program, please reach out to your local lomitapide medical representative or go to our website, www.novelion.com.

Applications must be submitted by the HealthCare Professional. Patient eligibility will be determined by Aegerion Pharmaceuticals in accordance with established policies and procedures. The acceptance and processing of this application does not guarantee that access to investigational product will be provided.

If you are approved for the Lomitapide Expanded Access Program, we may follow up with you from time to time to obtain updated information.